Clinical Trials Logo

Concurrent Chemoradiotherapy clinical trials

View clinical trials related to Concurrent Chemoradiotherapy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06391190 Recruiting - Immunotherapy Clinical Trials

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

Start date: January 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the safety and efficacy of Albumin-Bound Paclitaxel/Platinum based concurrent chemoradiotherapy Followed by PD-1 inhibitor (Sintilimab) in locally advanced cervical cancer

NCT ID: NCT06378840 Recruiting - Immunotherapy Clinical Trials

the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

Start date: January 1, 2022
Phase:
Study type: Observational

To explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy Followed by PD-1 inhibitor

NCT ID: NCT05944809 Recruiting - Esophageal Cancer Clinical Trials

The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients

Start date: July 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this interventional study is to explore the protective effect of prophylactic TPO combined with bone marrow sparing (BMS)-IMRT in patients with esophageal cancer undergoing concurrent chemoradiotherapy. The main purpose is to reduce the incidence of all grades of thrombocytopenia from 35% to less than 10% by the intervention of study. Participants will initiate concurrent chemoradiotherapy within 2 weeks after enrollment,and they will receive subcutaneous injection of recombinant human thrombopoietin (rhTPO) 15000U once a week during the radiotherapy.

NCT ID: NCT03963882 Recruiting - Laparoscopy Clinical Trials

NAC Followed by RH for the Treatment of LACC

Start date: June 19, 2019
Phase: Phase 2
Study type: Interventional

This cohort study is to evaluate the role of neoadjuvant chemotherapy (NAC) in the treatment of locally advanced cervical cancer (LACC). Sixty patients with LACC (FIGO 2009 stage IB2 to IIB) will be enrolled. After informed consents, they would accept the imaging evaluation of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET). After excluding cases of distant metastasis, they will accept two cycles of NAC (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks). Then a second MRI is performed to evaluate the imaging response. For patients achieving objective response, radical hysterectomy (RH, via laparoscopy or laparotomy) and an evaluation of pathologic response are performed. For patients without objective imaging response, the choice of concurrent chemoradiotherapy or radical hysterectomy will be discussed. After RH, adjuvant therapy will be given according to the RH pathologic results. The primary objectives consist of (1) the objective imaging response after NAC; (2) the objective pathologic response after RH. The secondary objectives consist of (1) disease-free survival and overall survival after various therapy modalities; (2) severe adverse effects of NAC; (3) the effects of NAC on the surgical outcomes.

NCT ID: NCT03908372 Recruiting - Clinical trials for Concurrent Chemoradiotherapy

Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma

Start date: June 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to optimize treatment strategies for patients with stage II and III nasopharyngeal carcinoma, reduce the side effects related to treatment and improve the quality of life.

NCT ID: NCT03579004 Recruiting - Clinical trials for Squamous Cell Carcinoma

Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer

Start date: July 10, 2017
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate efficacy and safety of neoadjuvant chemotherapy followed by preoperative chemoradiotherapy in patients with resectable esophageal squamous cell carcinoma

NCT ID: NCT01180166 Recruiting - Gastric Cancer Clinical Trials

Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The prognosis of patients with inoperable locally advanced or residual/relapsed gastric cancer is rather poor. Concurrent capecitabine chemoradiotherapy is safe and recommended. Nimotuzumab, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody, has shown its antitumor safety and efficiency in many phase I/II studies. Efficiency of combination of these treatment need to be further analyzed.